InflaRx ( (IFRX) ) has issued an announcement.
On April 24, 2025, InflaRx N.V. held its Annual General Meeting of Shareholders, where several key resolutions were approved. Shareholders adopted the Dutch statutory annual accounts for 2024, appointed KPMG for the 2025 audit, and released directors from liability for 2024. Additionally, they extended the board’s authorization to issue shares, limit pre-emption rights, and acquire shares. An amendment to the company’s articles of association was also approved, reflecting changes in the authorized share capital structure. These decisions are expected to enhance InflaRx’s operational flexibility and strategic capabilities.
Spark’s Take on IFRX Stock
According to Spark, TipRanks’ AI Analyst, IFRX is a Neutral.
InflaRx’s overall stock score reflects significant challenges in financial performance, with persistent losses and cash flow issues being prominent concerns. The technical analysis indicates bearish momentum, while valuation metrics suggest potential overvaluation given the negative P/E ratio. These factors combined make the stock less attractive at this time.
To see Spark’s full report on IFRX stock, click here.
More about InflaRx
InflaRx N.V. is a company operating in the biotechnology industry, focusing on developing treatments for inflammatory diseases. The company is based in Jena, Germany, and is known for its work on complement system inhibitors.
YTD Price Performance: -52.00%
Average Trading Volume: 408,202
Technical Sentiment Signal: Buy
Current Market Cap: $77.87M
See more insights into IFRX stock on TipRanks’ Stock Analysis page.